Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids

Journal of Molecular Endocrinology

Volumn 51, Issue 3, 2013, Pages 277-286

  Giandomenico, Valeria ^a   Cui, Tao ^b   Grimelius, Lars ^b   Öberg, Kjell ^a,b   Pelosi, Giuseppe ^c,d   Tsolakis, Apostolos V ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Lung carcinoids; Novel target for diagnosis; Octreo scan; Olfactory receptor 51E1; Somatostatin receptors

Indexed keywords

MESSENGER RNA; OLFACTORY RECEPTOR 51E1; PENTETREOTIDE; PROTEIN; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG CANCER; LUNG CARCINOID; LYMPH NODE METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SEQUENCE ANALYSIS;

LUNG CARCINOIDS; NOVEL TARGET FOR DIAGNOSIS; OCTREOSCAN; OLFACTORY RECEPTOR 51E1; SOMATOSTATIN RECEPTORS;

CARCINOID TUMOR; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, SOMATOSTATIN;

EID: 84887389854     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-13-0144     Document Type: Article

References (28)

1. Ache BW & Young JM 2005 Olfaction: diverse species, conserved principles. Neuron 48 417-430. (doi:10.1016/j.neuron.2005.10.022)
2. Beasley M. B, Thunnissen FB, Hasleton PS, Barbareschi M, Pugatch B, Geisinger K., Brambilla E, Gazdar A & Travis WD 2004 Carcinoid tumour. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, 3rd edn, pp 59-62. EdsWDTravis, E Brambilla, HK Muller-Hermelink & CC Harris Lyon, France: IARC Press
3. van Buren G II, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, Somcio R, Fan F., Camp ER, Yao JC et al. 2007 The development and characterization of a human midgut carcinoid cell line. Clinical Cancer Research 13 4704-4712. (doi:10.1158/1078-0432.CCR-06-2723)
4. Cui T., Tsolakis AV, Li SC, Cunningham JL, Lind T, Oberg K & Giandomenico V. 2013 Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas. European Journal of Endocrinology 168 253-261. (doi:10.1530/EJE-12-0814)
5. van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO & Kwekkeboom D. J 2007a Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. European Journal of Nuclear Medicine and Molecular Imaging 34 1219-1227. (doi:10.1007/s00259-006-0355-4)
6. van Essen M, Krenning EP, De Jong M, Valkema R & Kwekkeboom DJ 2007b Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 46 723-734. (doi:10.1080/02841860701441848)
7. Filosso P. L, Rena O, Donati G, Casadio C, Ruffini E, Papalia E, Oliaro A & Maggi G. 2002a Bronchial carcinoid tumors: surgical management and long-term outcome. Journal of Thoracic and Cardiovascular Surgery 123 303-309. (doi:10.1067/mtc.2002.119886)
8. Filosso P. L, Ruffini E, Oliaro A, Papalia E, Donati G & Rena O 2002b Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. European Journal of Cardio-Thoracic Surgery 21 913-917. (doi:10.1016/S1010-7940(02)00055-6)
9. Fuessel S., Weigle B, Schmidt U, BarettonG, Koch R, Bachmann M, Rieber EP, Wirth M. P & Meye A 2006 Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs. Cancer Letters 236 95-104. (doi:10.1016/j.canlet.2005.05.005)
10. Fujita Y., Takahashi T, Suzuki A, Kawashima K, Nara F & Koishi R 2007 Deorphanization of Dresden G protein-coupled receptor for an odorant receptor. Journal of Receptor and Signal Transduction Research 27 323-334. (doi:10.1080/10799890701534180)
11. Gustafsson B. I, Kidd M, Chan A, Malfertheiner MV & Modlin IM 2008 Bronchopulmonary neuroendocrine tumors. Cancer 113 5-21. (doi:10.1002/cncr.23542)
12. Knowles S. M & Wu AM 2012 Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. Journal of Clinical Oncology 30 3884-3892. (doi:10.1200/JCO.2012.42.4887)
13. Korner M, Waser B, Schonbrunn A, Perren A & Reubi JC 2012 Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. American Journal of Surgical Pathology 36 242-252. (doi:10.1097/PAS.0b013e31823d07f3)
14. Kwekkeboom D. J, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders R. A, van Eijck CH, Esser JP, Kam BL & Krenning EP 2005 Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3)octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology 23 2754-2762. (doi:10.1200/JCO.2005.08.066)
15. Kwekkeboom D. J, de Herder WW & Krenning EP 2011 Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 173-185, ix. (doi:10.1016/j.ecl.2010.12.003)
16. Leja J., Essaghir A, Essand M, Wester K, Oberg K, Tötterman TH, Lloyd R, Vasmatzis G., Demoulin JB & Giandomenico V 2009 Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Modern Pathology 22 261-272. (doi:10.1038/modpathol.2008.174)
17. Modlin I. M, Kidd M, Pfragner R, Eick GN & Champaneria MC 2006 The functional characterization of normal and neoplastic human enterochromaffin cells. Journal of Clinical Endocrinology and Metabolism 91 2340-2348. (doi:10.1210/jc.2006-0110)
18. Olender T., Lancet D & Nebert DW 2008 Update on the olfactory receptor (OR) gene superfamily. Human Genomics 3 87-97. (doi:10.1186/ 1479-7364-3-1-87)
19. Papotti M., Croce S, Bello M, Bongiovanni M, Allia E, Schindler M & Bussolati G. 2001 Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Archiv: an International Journal of Pathology 439 787-797. (doi:10.1007/ s004280100494)
20. Pelosi G., Volante M, Papotti M, Sonzogni A, Masullo M & Viale G 2006 Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging 50 272-287.
21. Righi L., Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, Inzani F, Pelosi G., Rindi G & Papotti M 2010 Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Annals of Oncology 21 548-555. (doi:10.1093/annonc/mdp334)
22. Saito H., Chi Q, Zhuang H, Matsunami H & Mainland JD 2009 Odor coding by a mammalian receptor repertoire. Science Signaling 2 ra9. (doi:10.1126/scisignal.2000016)
23. Tsuta K, Wistuba II & Moran CA 2012 Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung. Pathology, Research and Practice 208 470-474. (doi:10.1016/j.prp.2012. 05.014)
24. Vanti W. B, Nguyen T, Cheng R, Lynch KR, George SR & O'Dowd BF 2003 Novel human G-protein-coupled receptors. Biochemical and Biophysical Research Communications 305 67-71. (doi:10.1016/S0006-291X (03)00709-5)
25. VolanteM, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L., Garancini S, Capella C et al. 2007 Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Modern Pathology 20 1172-1182. (doi:10.1038/modpathol.3800954)
26. Wang J., Weng J, Cai Y, Penland R, Liu M & Ittmann M 2006 The prostatespecific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to a-methylacyl-CoA racemase. Prostate 66 847-857. (doi:10.1002/pros.20389)
27. Weigle B., Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger M. A, Meye A, Bachmann M et al. 2004 D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochemical and Biophysical Research Communications 322 239-249. (doi:10.1016/j.bbrc.2004.07.106)
28. Weng J., Wang J, Hu X, Wang F, Ittmann M & Liu M 2006 PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. International Journal of Cancer 118 1471-1480. (doi:10.1002/ijc.21527)